Compare DexCom, Inc. (DXCM) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Liberty Global Ltd Class C — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Liberty Global Ltd Class C trades at $8.52 (market cap $3.06B). The key difference: DexCom, Inc. is far larger — about 10.4× Liberty Global Ltd Class C's market cap, and DexCom, Inc. is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Liberty Global Ltd Class C for 21 Days on average.
| DXCM | LBTYK | |
|---|---|---|
Market Cap | $31.86B | $3.06B |
Volume | 3,607,070 | 2,508,956 |
Sector | Health | Media |
52-Week High | $92.34 | $12.67 |
52-Week Low | $54.84 | $8.52 |
Typical Hold Time | 62 Days | 21 Days |
Enterprise Value | $31.32B | $9.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
LBTYK trades at $8.75, near its 52-week low, reflecting a bearish technical trend with weak moving averages and oscillators. Fundamentally, the company reported a net loss of -$7.14B in 2025 despite $4.88B in revenue, though 2026 shows improvement with a reduced loss of -$3.0B. Recent strategic moves include the Ziggo Group spin-off preparation and an AI partnership to enhance customer experience.
The stock presents a high-risk opportunity with a discounted valuation (P/S 0.61, P/B 0.32) and strong analyst support (69% buy ratings, $12.67 target). Key risks are persistent losses and execution challenges, but upside potential exists if Ziggo's 2027 listing and cost controls drive profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
